Myovant Sciences Good News
A lot of positive news is emanating from clinical trials conducted by development-stage biotechnology firms and revenue-generating firms. The good news in the small development-stage firms becomes more interesting when the trial results are from Phase 3 trials and other late Phase trials. The cancer news that attracted the attention of the specialists and analysts who followed up on the presentations made at the American Society of Clinical Oncology's (ASCO20) Virtual simultaneous program was what was presented on May 29 by the firm Myovant Sciences (This content is for paid subscribers.